Loading...
XNASBNTC
Market cap256mUSD
Jan 16, Last price  
11.06USD
1D
2.60%
1Q
-3.66%
Jan 2017
-51.81%
IPO
-96.82%
Name

Benitec Biopharma Inc

Chart & Performance

D1W1MN
XNAS:BNTC chart
P/E
—
P/S
1,188.77
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
140.56%
Rev. gr., 5y
-54.69%
Revenues
216k
+188.00%
545,7341,017,756829,127346,506450,311455,44611,316,77797,00059,00073,00075,000216,000
Net income
-22m
L+11.19%
0000002,867,187-8,301,000-13,781,000-18,562,000-19,562,000-21,751,000
CFO
-19m
L+7.72%
-9,271,000-9,692,000-9,692,000-20,208,000-8,304,00004,790,000-7,535,000-12,832,000-15,899,000-18,012,000-19,403,000
Earnings
Feb 11, 2025

Profile

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
URL
https://benitec.com/
IPO date
Jul 11, 2012
Employees
18
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
216
188.00%
75
2.74%
73
23.73%
Cost of revenue
22,706
19,537
17,927
Unusual Expense (Income)
NOPBT
(22,490)
(19,462)
(17,854)
NOPBT Margin
Operating Taxes
(619)
3
354
Tax Rate
NOPAT
(21,871)
(19,465)
(18,208)
Net income
(21,751)
11.19%
(19,562)
5.39%
(18,562)
34.69%
Dividends
Dividend yield
Proceeds from repurchase of equity
73,921
17,884
BB yield
-260.46%
-5,410.91%
Debt
Debt current
284
275
252
Long-term debt
284
843
1,370
Deferred revenue
Other long-term liabilities
38
Net debt
(50,298)
(1,359)
(2,440)
Cash flow
Cash from operating activities
(19,403)
(18,012)
(15,899)
CAPEX
(179)
(1,000)
(13)
Cash from investing activities
(179)
(1,000)
(13)
Cash from financing activities
68,029
16,015
FCF
(21,707)
(19,085)
(18,624)
Balance
Cash
50,866
2,477
4,062
Long term investments
Excess cash
50,855
2,473
4,058
Stockholders' equity
(191,150)
(168,719)
(149,571)
Invested Capital
238,720
170,620
153,264
ROIC
ROCE
EV
Common stock shares outstanding
4,060
1,386
481
Price
6.99
2,830.82%
0.24
-79.44%
1.16
-72.71%
Market cap
28,381
8,486.74%
331
-40.72%
558
-48.07%
EV
(21,917)
(1,028)
(1,882)
EBITDA
(22,147)
(19,081)
(17,462)
EV/EBITDA
0.99
0.05
0.11
Interest
904
33
32
Interest/NOPBT